首页> 外文期刊>Chemico-biological interactions >HSD17B1 expression enhances estrogen signaling stimulated by the low active estrone, evidenced by an estrogen responsive element-driven reporter gene in vivo
【24h】

HSD17B1 expression enhances estrogen signaling stimulated by the low active estrone, evidenced by an estrogen responsive element-driven reporter gene in vivo

机译:HSD17B1表达增强了低活性雌酮刺激的雌激素信号传导,体内有雌激素反应性元件驱动的报告基因证明了这一点

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Hydroxysteroid (17beta) dehydrogenase 1 (HSD17B1) belongs to a family of short-chain-dehydrogenases. The enzyme utilizes NAD(P) and NAD(P)H as cofactors, and catalyzes the reversible reaction between estrone (El) and estradiol (E2) in vitro. Of these steroids, El presents with lower estrogenic activity, but is converted to highly active E2 by HSD17B1. HSD17B1 is expressed especially in tissues with a high E2-producing capacity such as human ovaries and placenta, but also in several peripheral estrogen target tissues in humans, and inhibiting the enzyme activity is, thus, considered a promising approach to treat estrogen-dependent diseases. By analyzing transgenic mice universally expressing human HSD17B1 and carrying estrogen-response element (ERE)-driven luciferase reporter gene (Bi-transgenic ERELuc-HSD17B1TG mice) we showed a markedly higher reporter gene activity in various peripheral tissues of these mice as compared with ERELuc mice, indicating enhanced estrogen response generated by human HSD17B1 expression. An increased response after El administration was also evident in the Bi-TG mice, indicated by the increased uterus growth response and by the higher ERELuc reporter gene activity in the uterus. Moreover, a HSD17B1 inhibitor significantly reduced E1-induced increase in the uterus weight and uterine epithelial proliferation in the Bi-TG mice. Also the E1-induced ERELuc activity in the inhibitor-treated uterus was reduced by the HSD17B1 inhibitor in immature mice ex vivo, as well as in the liver of adult mice. The data, thus, demonstrate the potential use of the Bi-TG mice as a preclinical in vivo model for screening the efficacy of HSD17B1 inhibitors. As compared with the existing models, the Bi-TG mice present with luciferase activity as an additional, easily quantitative endpoint for the estrogen action. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
机译:羟基类固醇(17beta)脱氢酶1(HSD17B1)属于短链脱氢酶家族。该酶利用NAD(P)和NAD(P)H作为辅因子,并在体外催化雌酮(E1)和雌二醇(E2)之间的可逆反应。在这些类固醇中,E1的雌激素活性较低,但被HSD17B1转化为高活性E2。 HSD17B1特别是在具有高E2产生能力的组织(例如人的卵巢和胎盘)中表达,而且在人的几种外周雌激素靶组织中表达,因此抑制酶活性被认为是治疗雌激素依赖性疾病的一种有前途的方法。通过分析普遍表达人类HSD17B1并带有雌激素响应元件(ERE)驱动的荧光素酶报道基因的转基因小鼠(Bi-转基因ERELuc-HSD17B1TG小鼠),我们发现,与ERELuc相比,这些小鼠各种外周组织中的报道基因活性明显更高小鼠,表明由人类HSD17B1表达产生的雌激素反应增强。在Bi-TG小鼠中,在施用E1后的应答也明显增加,这由子宫生长应答增加和子宫中较高的ERELuc报告基因活性所表明。此外,在Bi-TG小鼠中,HSD17B1抑制剂可显着降低E1诱导的子宫重量增加和子宫上皮增殖。 HSD17B1抑制剂在离体的未成熟小鼠体内以及成年小鼠的肝脏中也降低了抑制剂治疗的子宫中E1诱导的ERELuc活性。因此,数据证明了Bi-TG小鼠作为临床前体内模型用于筛选HSD17B1抑制剂功效的潜在用途。与现有模型相比,Bi-TG小鼠具有萤光素酶活性,是雌激素作用的另外一个易于定量的终点。 (C)2015 Elsevier Ireland Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号